Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

The top ex­per­i­men­tal drug stem­ming from John­son & John­son’s long-run­ning al­liance with Ad­dex Ther­a­peu­tics has failed a Phase 2 epilep­sy study, cast­ing a shad­ow over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER